Marketdash
Back to News

Cannabis ETFs Surge on Trump's Marijuana Reclassification Hint—But Will It Stick?

MarketDash Editorial Team
12 hours ago
President Trump's comments about potentially reclassifying marijuana sent cannabis ETFs soaring this week. Funds like WEED, MSOS, and CNBS jumped as investors bet on policy change, but the real question is whether this rally has staying power or if it's just another policy-driven head fake.

Nothing gets a niche sector moving quite like a presidential sound bite, and cannabis ETFs just got a big one. President Donald Trump announced Monday that he's mulling an executive order to reclassify marijuana as a less dangerous substance, and investors didn't wait around for the fine print.

"We are looking at that very strongly," Trump said, referring to the possibility of moving marijuana to Schedule III from Schedule I under the Controlled Substances Act. Sure, no final decision has been made, and yes, the Drug Enforcement Administration still needs to sign off on any change. But markets aren't exactly known for their patience, and cannabis ETFs took off like someone just legalized optimism.

The Rally Is Real

The Roundhill Cannabis ETF (WEED) hit a 52-week high on Tuesday, rocketing over 226% from its 52-week low. That's the kind of move that makes you remember why regulatory news matters so much in cannabis investing. WEED offers broad exposure to cannabis operations and related companies, making it a go-to fund when the sector catches fire.

And it wasn't alone. The AdvisorShares Pure US Cannabis ETF (MSOS), Amplify Seymour Cannabis ETF (CNBS), Amplify Alternative Harvest ETF (MJ), and AdvisorShares Pure Cannabis ETF (YOLO) all posted strong gains as investors priced in the possibility of meaningful policy change.

Why Reclassification Actually Matters

For ETF investors, this isn't just another momentum trade. Moving marijuana to Schedule III could represent a genuine structural shift. Federal restrictions have historically made it nearly impossible for cannabis companies to access normal banking and lending, forcing them into expensive, high-rate financing arrangements that squeeze margins and stunt growth.

Reclassification could change all that. It might ease lending requirements, reduce punishing tax burdens, improve profit margins, and finally let institutional investors participate without regulatory anxiety. Those are the kinds of developments that directly benefit ETF portfolios holding companies that actually grow, process, or sell cannabis.

ETFs often serve as the first institutional entry point for emerging or previously restricted industries. They provide diversified exposure to volatile, fragmented markets where picking individual winners is risky. Cannabis fits that profile perfectly.

Still Plenty of Risk

Here's the reality check: cannabis ETFs remain extremely sensitive to policy timelines and whether officials actually follow through. A White House official said last week that no final decision has been reached. And if you've been watching cannabis investing for any length of time, you know that rallies have faded before when reforms stalled or disappeared entirely.

Right now, cannabis ETFs are behaving like high-octane policy trades—volatile, reactive, and driven by headlines rather than fundamentals. But if Schedule III actually becomes reality, this could mark the moment the sector finally transitions from regulatory gray zone to something more durable and genuinely investable. The question is whether this time is different, or just another round trip.

Back to News

Cannabis ETFs Surge on Trump's Marijuana Reclassification Hint—But Will It Stick?

MarketDash Editorial Team
12 hours ago
President Trump's comments about potentially reclassifying marijuana sent cannabis ETFs soaring this week. Funds like WEED, MSOS, and CNBS jumped as investors bet on policy change, but the real question is whether this rally has staying power or if it's just another policy-driven head fake.

Nothing gets a niche sector moving quite like a presidential sound bite, and cannabis ETFs just got a big one. President Donald Trump announced Monday that he's mulling an executive order to reclassify marijuana as a less dangerous substance, and investors didn't wait around for the fine print.

"We are looking at that very strongly," Trump said, referring to the possibility of moving marijuana to Schedule III from Schedule I under the Controlled Substances Act. Sure, no final decision has been made, and yes, the Drug Enforcement Administration still needs to sign off on any change. But markets aren't exactly known for their patience, and cannabis ETFs took off like someone just legalized optimism.

The Rally Is Real

The Roundhill Cannabis ETF (WEED) hit a 52-week high on Tuesday, rocketing over 226% from its 52-week low. That's the kind of move that makes you remember why regulatory news matters so much in cannabis investing. WEED offers broad exposure to cannabis operations and related companies, making it a go-to fund when the sector catches fire.

And it wasn't alone. The AdvisorShares Pure US Cannabis ETF (MSOS), Amplify Seymour Cannabis ETF (CNBS), Amplify Alternative Harvest ETF (MJ), and AdvisorShares Pure Cannabis ETF (YOLO) all posted strong gains as investors priced in the possibility of meaningful policy change.

Why Reclassification Actually Matters

For ETF investors, this isn't just another momentum trade. Moving marijuana to Schedule III could represent a genuine structural shift. Federal restrictions have historically made it nearly impossible for cannabis companies to access normal banking and lending, forcing them into expensive, high-rate financing arrangements that squeeze margins and stunt growth.

Reclassification could change all that. It might ease lending requirements, reduce punishing tax burdens, improve profit margins, and finally let institutional investors participate without regulatory anxiety. Those are the kinds of developments that directly benefit ETF portfolios holding companies that actually grow, process, or sell cannabis.

ETFs often serve as the first institutional entry point for emerging or previously restricted industries. They provide diversified exposure to volatile, fragmented markets where picking individual winners is risky. Cannabis fits that profile perfectly.

Still Plenty of Risk

Here's the reality check: cannabis ETFs remain extremely sensitive to policy timelines and whether officials actually follow through. A White House official said last week that no final decision has been reached. And if you've been watching cannabis investing for any length of time, you know that rallies have faded before when reforms stalled or disappeared entirely.

Right now, cannabis ETFs are behaving like high-octane policy trades—volatile, reactive, and driven by headlines rather than fundamentals. But if Schedule III actually becomes reality, this could mark the moment the sector finally transitions from regulatory gray zone to something more durable and genuinely investable. The question is whether this time is different, or just another round trip.